Phase III studies are ongoing on Dupixent for chronic pruritus of unknown origin and lichen simplex chronicus. In 2024, Dupixent generated global product sales of $€13.07 billion ($14.15 billion ...
Biopsy specimens from the labia majora and the vulva showed chronic dermatitis and lichen simplex chronicus. The patient denied having used tampons, pads, douches, condoms, or other genital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback